Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says - 2Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- 3French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- 4Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- 5Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- Energy agency chief warns of 'black April' for oil supplies
- ‘Aid for Ukraine’ pierogi fundraiser event
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- 'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 6 Solid Moving Administrations for a Calm Movement
- Planet-eating stars hint at Earth's ultimate fate
